HomeCompareBBLU vs ABBV

BBLU vs ABBV: Dividend Comparison 2026

BBLU yields 1.30% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $83.2K in total portfolio value
10 years
BBLU
BBLU
● Live price
1.30%
Share price
$14.71
Annual div
$0.19
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.5K
Annual income
$141.40
Full BBLU calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — BBLU vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBLUABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBLU + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBLU pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBLU
Annual income on $10K today (after 15% tax)
$110.48/yr
After 10yr DRIP, annual income (after tax)
$120.19/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,746.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBLU + ABBV for your $10,000?

BBLU: 50%ABBV: 50%
100% ABBV50/50100% BBLU
Portfolio after 10yr
$63.1K
Annual income
$12,933.56/yr
Blended yield
20.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BBLU
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBLU buys
0
ABBV buys
0
No recent congressional trades found for BBLU or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBLUABBV
Forward yield1.30%3.12%
Annual dividend / share$0.19$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$21.5K$104.7K
Annual income after 10y$141.40$25,725.73
Total dividends collected$1.4K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BBLU vs ABBV ($10,000, DRIP)

YearBBLU PortfolioBBLU Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,830$129.98$11,559$438.51$729.00ABBV
2$11,720$131.56$13,494$640.86$1.8KABBV
3$12,673$133.05$15,951$945.97$3.3KABBV
4$13,695$134.46$19,152$1,413.89$5.5KABBV
5$14,789$135.79$23,443$2,146.38$8.7KABBV
6$15,961$137.05$29,391$3,321.96$13.4KABBV
7$17,217$138.24$37,948$5,265.87$20.7KABBV
8$18,561$139.36$50,795$8,596.74$32.2KABBV
9$20,001$140.41$71,034$14,549.41$51.0KABBV
10$21,543$141.40$104,715$25,725.73$83.2KABBV

BBLU vs ABBV: Complete Analysis 2026

BBLUStock

The fund is an actively managed exchange-traded fund ("ETF") sub-advised by Bridgeway Capital Management, LLC (the "Sub-Adviser") that seeks to achieve its investment objective by investing primarily in blue-chip stocks, and through some income almost exclusively derived from dividends paid by companies held in the fund's portfolio.

Full BBLU Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BBLU vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBLU vs SCHDBBLU vs JEPIBBLU vs OBBLU vs KOBBLU vs MAINBBLU vs JNJBBLU vs MRKBBLU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.